SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

         Date of Report (date of earliest event reported): June 6, 2012


                                 BIOCUREX, INC.
                       ----------------------------------
                 (Name of Small Business Issuer in its charter)

           Texas                        0-26947                 75-2742601
----------------------------       ------------------        ------------------
(State or other jurisdiction     (Commission File No.)       (IRS Employer
of incorporation)                                            Identification No.)

                           7080 River Road, Suite 215
                   Richmond, British Columbia , Canada V6X 1X5
                   -------------------------------------------
          (Address of Principal Executive Offices, including Zip Code)

       Registrant's telephone number, including area code: (866) 884-8669

                                       N/A
                    ---------------------------------------
          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy  the filing  obligation  of the  registrant  under any of the  following
provisions (see General Instruction A.2. below)


[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement  communications  pursuant  to  Rule  13e-14(c)  under  the
    Exchange Act (17 CFR 240.13e-4(c))


<PAGE>


Item 3.02.  Unregistered Sales of Equity Securities.


     During the twelve months ended August 31, 2012 the Company sold  84,684,615
shares of its common stock to private investors for a total amount of $576,632.

     No commissions were paid in connection with the sale of these securities.

     The Company relied upon the exemption from registration provided by Section
4(2) of the Securities  Act of 1933 with respect to the sale of the shares.  The
purchasers of these  securities were  sophisticated  investors who were provided
full information  regarding the Company's business and operations.  There was no
general  solicitation in connection with the offer or sale of these  securities.
The  purchasers  acquired  these  securities  for their own account.  The shares
cannot be sold unless  pursuant to an  effective  registration  statement  or an
exemption from registration.

                                       2


<PAGE>



                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


Date:  August 23, 2012               BIOCUREX, INC.


                                     By: /s/ Ricardo Moro
                                         -------------------------------------
                                         Dr. Ricardo Moro, Chief Executive
                                         Officer

                                       3

<PAGE>
[{"type": "8-K", "sequence": "1", "filename": "form8kitem302aug-12.txt", "description": "FORM 8-K ITEM 3.02", "secsgml_size_bytes": 3568}]
{"company-data": {"conformed-name": "BIOCUREX INC", "cik": "0001092562", "assigned-sic": "3841", "irs-number": "752742601", "state-of-incorporation": "A1", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-26947", "film-number": "121053636"}, "business-address": {"street1": "7080 RIVER RD", "street2": "STE 215", "city": "RICHMOND", "state": "A1", "zip": "V6X 1X5", "phone": "6042079150"}, "mail-address": {"street1": "7080 RIVER RD", "street2": "STE 215", "city": "RICHMOND", "state": "A1", "zip": "V6X 1X5"}, "former-company": {"former-conformed-name": "WHISPERING OAKS INTERNATIONAL INC", "date-changed": "19990804"}}
SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

         Date of Report (date of earliest event reported): June 6, 2012

                                 BIOCUREX, INC.
                       ----------------------------------
                 (Name of Small Business Issuer in its charter)

           Texas                        0-26947                 75-2742601
----------------------------       ------------------        ------------------
(State or other jurisdiction     (Commission File No.)       (IRS Employer
of incorporation)                                            Identification No.)

                           7080 River Road, Suite 215
                   Richmond, British Columbia , Canada V6X 1X5
                   -------------------------------------------
          (Address of Principal Executive Offices, including Zip Code)

       Registrant's telephone number, including area code: (866) 884-8669

                                       N/A
                    ---------------------------------------
          (Former name or former address if changed since last report)

Check appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy  the filing  obligation  of the  registrant  under any of the  following
provisions (see General Instruction A.2. below)

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
    230.425)

[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17 CFR
    240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement  communications  pursuant  to  Rule  13e-14(c)  under  the
    Exchange Act (17 CFR 240.13e-4(c))
Item 3.02.  Unregistered Sales of Equity Securities.

     During the twelve months ended August 31, 2012 the Company sold  84,684,615
shares of its common stock to private investors for a total amount of $576,632.

     No commissions were paid in connection with the sale of these securities.

     The Company relied upon the exemption from registration provided by Section
4(2) of the Securities  Act of 1933 with respect to the sale of the shares.  The
purchasers of these  securities were  sophisticated  investors who were provided
full information  regarding the Company's business and operations.  There was no
general  solicitation in connection with the offer or sale of these  securities.
The  purchasers  acquired  these  securities  for their own account.  The shares
cannot be sold unless  pursuant to an  effective  registration  statement  or an
exemption from registration.

                                       2
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Date:  August 23, 2012               BIOCUREX, INC.

                                     By: /s/ Ricardo Moro
                                         -------------------------------------
                                         Dr. Ricardo Moro, Chief Executive
                                         Officer

                                       3